Agouti-related Peptide (AgRP) in Healthy Mothers and Mothers With Preeclampsia and Their Offspring

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

84 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is focused on the investigation of possible associations between plasma/serum levels of agouti related peptide (AgRP) and its genetic background in healthy women with physiological pregnancy (non-preeclamptic) and women with preeclampsia, in the postpartum period, and in their offspring.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prediction of Adverse Perinatal Outcome for Preeclampsia in Sichuan Province of China

NCT01804751

Preeclampsia

UNKNOWN

Prediction of Preeclampsia by Comprehensive Markers.

NCT03665623

Pre-Eclampsia

COMPLETED

Cardiovascular Risk After Preeclampsia

NCT05277233

Preeclampsia

RECRUITING

Serpin C and Soluble Fms-like Tyrosine Kinase-1 Levels in Normotensive Pregnant Women May Predict the Development of Preeclampsia

NCT06214702

Pre-Eclampsia

COMPLETED

Molecular Study of the Maternal-fetal Interface in Preeclampsia.

NCT06232668

Preeclampsia

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is focused on investigation of possible genotype-phenotype interactions of agouti-related peptide (AgRP) in postpartum non-preeclamptic women and preeclamptic women and in their offspring.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preeclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mothers, preeclampsia

Mothers with preeclampsia diagnosed according to the Guidelines by the Czech Society of obstetrics and gynecology as development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (\>300 mg of urinary protein/L over 24 h).

No interventions assigned to this group

Newborns, physiological pregnancy-delivery

The newborns from the physiological pregnancies with spontaneous, uncomplicated delivery.

No interventions assigned to this group

Newborns, pregnancy with preeclampsia

Newborns from the pregnancies complicated by preeclampsia.

No interventions assigned to this group

Mothers, Physiological pregnancy-labour

The cohort of non-preeclamptic mothers with physiological, uncomplicated conception, pregnancy and delivery.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For preeclampsia:

* development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (\>300 mg of urinary protein/L over 24 h)
* single-fetus pregnancy
* age range 18-35 y
* no preconceptional history of hypertension
* For mother with physiological pregnancies:

* uncomplicated
* spontaneous conception
* single-fetus pregnancy
* age range 18-35 y
* spontaneous uncomplicated delivery
* no history of preconceptional hypertension

Exclusion Criteria

* For preeclampsia:

* multiple pregnancy
* preeclampsia superimposed to chronic hypertension preceding pregnancy
* kidney disease
* fetal malformations
* For mothers with physiological pregnancies:

* in vitro fertilization
* fetal malformations
* multiple pregnancy
* events of bleeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No